Abstract
The search for new agents for the therapy of autoimmune diseases and transplantation is a continuous and often frustrating task. For rheumatoid arthritis (RA), a chronic inflammatory immune-mediated disease, that leads to severe damage of the articular cartilage and subchondral bone, there is no one agent or combination of agents fully capable of stopping disease progression or reversing the damage. First line therapy consists of nonsteroidal anti-inflammatory drugs (NSAIDs). This is followed by the use of disease-modifying antirheumatic drugs (DMARDs), also called slow acting antirheumatic drugs (SAARDs), whose mechanisms of action are not well defined. Some DMARDs are currently used because of clinical observations made during treatment of other diseases (Kavanaugh and Lipsky, 1992). For example, gold compounds which were initially used for the treatment of tuberculosis, were introduced for rheumatoid arthritis due to certain similarities between the two diseases and the belief that they might both be caused by a mycobacterium. An improvement in arthritic lesions in malaria patients treated with mepacrine prompted clinical trials with chloroquine and hydroxychloroquine. D-penicillamine, first used in the treatment of Wilson’s disease, was found to cause dissociation of macroglobulins, including IgM rheumatoid factor in vitro and formed the basis for its use in RA.
Keywords
- Suppressor Cell
- Alkyl Substitution
- Suppressor Cell Activity
- Natural Suppressor
- Suppressor Cell Induction
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albrightson CR, Bugelski PJ, Berkhout TA, Jackson B, Kerns WD, Organ AJ, Badger AM (1995): Separation of immunomodulatory and cholesterol lowering activities of heterocyclic azaspiranes. J Pharm Exp Ther 272: 689–698
Albrightson-Winslow CR, Brickson B, King A, Olivera D, Short B, Saunders C, Badger AM (1990): Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J Pharm Exp Ther 255(1): 382–387
Badger AM, Albrightson-Winslow CR, Kupiec-Weglinski JW (1991a): SK&F 105685: A novel immunosuppressive compound with efficacy in animal models of autoimmunity and transplantation. Trans Proc 23(1): 194–195
Badger AM, DiMartino MJ, Schmitt TC, Swift BA, Mirabelli CK (1987): Suppressor cell induction by the anticancer drug Spirogermanium. Int J Immunopharmac 9(5): 621–630
Badger AM, DiMartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N (1989): Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes. Int J Immunopharmac 11(7): 839–846
Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N (1990a): Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685. J Autoimmun 3: 485–500
Badger AM, Mirabelli CK, DiMartino MJ (1985): Generation of suppressor cells in normal rats by treatment with Spirogermanium, a novel heterocyclic anticancer drug. Immunopharmacol 10: 201–207
Badger AM, Schwartz DA, Picker DH, Dorman JW, Bradley FC, Cheeseman EN, DiMartino MJ, Hanna N, Mirabelli CK (1990b): Anti-arthritic and suppressor cell-inducing activity of the azaspiranes: Structure-function relationships of a novel class of immunomodulatory agents. J Med Chem 33: 2963–2970
Badger AM, Swift BA, Bugelski PJ (1993b): Suppressor cell (SC) activity induced by the azaspiranes may reside in a non-adherent or semi-adherent tissue macrophage population. AAI/CIS, Denver, Colorado, April 21–25
Badger AM, Swift BA, Bugelski PJ, High WB, DiMartino MJ, Greig R (1991b): The effect of SK&F 105685, a novel suppressor cell-inducing compound, in the adjuvant arthritic rat. Br J Rheum 30: 66
Badger AM, Swift BA, Webb EF, Clark RK, Bugelski PJ, Griswold DE (1993a): Beneficial effects of SK&F 105685 in rat adjuvant arthritis: Prophylactic and therapeutic effects on disease parameter progression. Int J Immunopharmac 15(3): 343–352
Boers M, Dijkmans BAC, van Rijthoven AWAM, Goeithè HS, Cats A (1990): Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 17: 38–42
DiMartino MJ, Lee JC, Badger AM, Muirhead KA, Mirabelli CK, Hanna N (1986): Antiarthritic and immunoregulatory activity of Spirogermanium. J Pharm Exp Ther 236(1): 103–110
Dougados M, Hassane A, Amor A (1988): Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 47: 127–133
Eichmann K (1988): Suppression needs a new hypothesis. Sc J Imm 28: 273–276
Fan P-Y, Best C, Coffman TM, Howell DN, Albrightson CR, Badger AM (1993): The azaspirane SK&F 105685 ameliorates renal allograaft rejection in rats. J Am Soc Nephrol 3: 1680–1685
Green DR, Webb DR. (1993): Saying the’ s’ word in public. Immunology Today 14(11): 523–525
Hancock WW, Schmidbauer G, Badger AM, Kupiec-Weglinski JW (1992): SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Trans Proc 24(1): 231–232
High WB, Bugelski PJ, Nichols ME, Swift BA, Solleveld HA, Badger AM (1994): Effects of a novel azaspirane (SK&F 105685) on the arthritic lesions in the adjuvant arthritic rat: Attenuation of the inflammatory process and preservation of skeletal integrity. J Rheumatol 21: 476–483
Kaplan JM, Badger AM, Ruggieri EV, Olivera DL, Newman-Tarr T, Bugelski PJ (1991): Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent. J Clin Lab Immunol 36: 49–58
Kaplan JM, Badger AM, Ruggieri EV, Swift BA, Bugelski PJ (1993): Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog. Int J Immunopharmac 15(2): 113–123
Kavanaugh AF, Lipsky PE (1992): Gold, penicillamine, antimalarials, and sulfasalazine. In: Inflammation: Basic Principles and Clinical Correlates, Gallin JI, Goldstein IM, Snyderman R, eds. New York: Raven Press
King AG, Badger AM (1991a): Administration of an immunomodulatory azaspi-rane, SK&F 105685, or human recombinant interleukin 1 stimulates myelopoie-sis and enhances survival from lethal irradiation in C57B1/6 mice. Exp Hematol 19: 624–628
King AG, Olivera D, Talmadge JE, Badger AM (1991b): Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspi-rane, SK&F 105685. Int J Immunopharmac 13(1): 91–100
Madhok R, Torley HI, Capell HA (1991): A study of the long-term efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 18: 1485–1489
Mirabelli CK, Badger AM, Sung C-P, Hillegass L, Sung C-M, Johnson RK, Picker D, Schwartz D, Dorman J, Martelucci S (1989): Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions. Anti-Cancer Drug Design 3: 231–242
Mitchison NA (1988): Suppressor activity as a composite property. Scand J Immunol 28: 271–276
Moller G (1988): Do suppressor T cells exist? Scand J Immunol 27: 247–250
Rabinovitch A, Suarez WL, Quin HY, Power RF, Badger AM (1993): Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 105685. J Autoimmun 1: 39–49
Rainsford KD (1990): Disease-modifying antirheumatic and immunoregulatory agents. Bailliere’s Clinical Rheumatology 4: 405–431
Rice LM, Wheeler JW, Geschickter CF (1974): Synthesis of 4.4-dialkyl-4-germa-cyclo-hexanone and 8.8 dialkyl-8-germaspiro(4.5)decanes. Journal of Heterocyclic Chemistry 11: 1041
Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW (1993): Induction of nonspecific X-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane. Transplantation 55: 1236–1243
Shoenfeld Y, Blank M, Aharoni R, Teitelbaum D, Arnon R (1993): Manipulation of autoimmune diseases with T-suppressor cells: Lessons from experimental SLE and EAE. Immunology Letters 36: 109–116
Strober S (1984): Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: Exploring obscure relationships. Ann Rev Immunol 2: 219–237
Thiem PA, Kaplan JM, Bugelski PJ, Ruggieri EV, Badger AM (1992): Induction of suppressor cell activity in vivo and suppression of lymphoproliferative responses in vitro by SK&F 105685 in the dog. Immunopharmacol 23: 67–74
Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, Chalmers A, Esdaile JM, Klinkhoff AV, Kraag GR, Ludwin D, Roberts RS (1990): Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335: 1051–1055
Waites CR, Bugelski PJ, Badger AM (1995): Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions. Toxicol App Pharmacol 130: 316–321
Westeren AC, Chan C-C, de Smet MD, Nussenblatt RB, Roberge FG (1993): Evaluation of the immunosuppressant SK&F 106610 in the treatment of experimental autoimmune uveoretinitis. Association for Research in Vision and Ophthalmology, May 2-7,1993, Sarasota, Florida
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Boston
About this chapter
Cite this chapter
Badger, A.M. (1995). Discovery and Development of the Immunomodulatory Azaspiranes. In: Merluzzi, V.J., Adams, J. (eds) The Search for Anti-Inflammatory Drugs. Birkhäuser Boston. https://doi.org/10.1007/978-1-4615-9846-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9846-6_10
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4615-9848-0
Online ISBN: 978-1-4615-9846-6
eBook Packages: Springer Book Archive